Herbort C P, de Smet M D, Roberge F G, Nussenblatt R B, FitzGerald D, Lorberboum-Galski H, Pastan I
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892.
Transplantation. 1991 Sep;52(3):470-4. doi: 10.1097/00007890-199109000-00015.
IL-2-PE40 is a recombinant chimeric protein composed of IL-2, fused to a modified pseudomonas exotoxin. This molecule is extremely toxic to activated T cells expressing high-affinity IL-2R. We used this new molecule for selective immunosuppression to treat corneal allograft rejection in the rat, using Fisher and Lewis rats, a strain combination differing only in medial and minor histocompatibility antigens. The effect of IL-2-PE40 on the immunologic response was studied using both a heterotopic corneal graft model and orthotopic grafts. At the dose of 0.31 micrograms/g given intraperitoneally every 12 hr, IL-2-PE40 produced a significant reduction of both total lymph node cells and cytotoxic-T-cell (CTL) activity in draining lymph nodes (DLN) of heterotopically grafted animals. IL-2-PE40 treatment also significantly reduced the clinical rejection score and cumulative rejection rate (CRR) in orthotopic grafts and appears to be a very effective immunosuppressive agent.
IL-2-PE40是一种重组嵌合蛋白,由白细胞介素-2(IL-2)与修饰的绿脓杆菌外毒素融合而成。该分子对表达高亲和力IL-2受体的活化T细胞具有极强的毒性。我们使用这种新分子进行选择性免疫抑制,以治疗大鼠角膜移植排斥反应,所用的Fisher大鼠和Lewis大鼠仅在内侧和次要组织相容性抗原方面存在差异。我们利用异位角膜移植模型和原位移植研究了IL-2-PE40对免疫反应的影响。以每12小时腹腔注射0.31微克/克的剂量给药时,IL-2-PE40可使异位移植动物引流淋巴结(DLN)中的总淋巴细胞和细胞毒性T细胞(CTL)活性显著降低。IL-2-PE40治疗还显著降低了原位移植的临床排斥评分和累积排斥率(CRR),似乎是一种非常有效的免疫抑制剂。